US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
ImmunityBio, Inc. - Common Stock
(NQ:
IBRX
)
10.29
+1.01 (+10.83%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ImmunityBio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 18, 2026
From
Schall Law
Via
GlobeNewswire
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
May 18, 2026
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
May 16, 2026
From
ImmunityBio, Inc.
Via
Business Wire
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 14, 2026
From
Schall Law
Via
GlobeNewswire
IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
May 14, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
May 14, 2026
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END
Via
FinancialNewsMedia
ImmunityBio, Inc. (IBRX) Action Lawsuit: Investors Face May 26, 2026, Deadline
May 13, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
ImmunityBio, Inc. (IBRX) Action Lawsuit: Investors Face May 26, 2026, Deadline
May 13, 2026
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
May 13, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
May 12, 2026
From
Kahn Swick & Foti, LLC
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
May 12, 2026
From
Pomerantz LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
May 12, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Who Have Suffered Losses - Contact Kaplan Fox before May 26, 2026 Lead Plaintiff Deadline
May 11, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Who Have Suffered Losses - Contact Kaplan Fox before May 26, 2026 Lead Plaintiff Deadline
May 11, 2026
NEW YORK, NY - May 11, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX)...
Via
TheNewswire.com
Topics
Lawsuit
ImmunityBio, Inc. Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit
May 11, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
ImmunityBio, Inc. Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit
May 11, 2026
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 11, 2026
From
Schall Law
Via
GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
May 10, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit
May 10, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit
May 10, 2026
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
INVESTOR DEADLINE REMINDER: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
May 09, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
INVESTOR DEADLINE REMINDER: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
May 09, 2026
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Securities Class Action Deadline Against ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan Fox Before May 26, 2026
May 09, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Securities Class Action Deadline Against ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan Fox Before May 26, 2026
May 09, 2026
NEW YORK, NY - May 9, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) on...
Via
TheNewswire.com
Topics
Lawsuit
IMMUNITYBIO CLASS ACTION DEADLINE: Kaplan Fox Encourages ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Contact the Firm Before the Lead Plaintiff Deadline on May 26, 2026
May 08, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
IMMUNITYBIO CLASS ACTION DEADLINE: Kaplan Fox Encourages ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Contact the Firm Before the Lead Plaintiff Deadline on May 26, 2026
May 08, 2026
NEW YORK, NY - May 8, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) on...
Via
TheNewswire.com
Topics
Lawsuit
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
May 07, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Deadline is May 26, 2026 to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan Fox
May 07, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Deadline is May 26, 2026 to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan Fox
May 07, 2026
NEW YORK, NY - May 7, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) on...
Via
TheNewswire.com
Topics
Lawsuit
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline
May 07, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
